This is a Phase I SBIR Application entitled Isolation and Characterization of Low Molecular Weight Compounds Derived from Plant Extracts that Activate the IRS-2 Dependent Insulin Signaling Cascade. Diabetes is a growing and significant global health concern. Insulin Receptor Substrate-2 (IRS-2) is a critical component in the insulin mediated signal transduction cascade which regulates glucose and lipid metabolism, insulin sensitivity, and the growth, function and survival of insulin-producing beta cells. Molecules that activate IRS-2 have the potential to help maintain glucose metabolism, increase insulin sensitivity, and increase insulin secretion by enhancing the function and viability of ?-cells. HPRL previously developed an IRS-2-specific assay system to identify leads that activate ectopically overproduced IRS-2 in 32DIRS-2 cells while having no effect on control 32D cells which lack detectable IRS-2. Using this cell-based assay, we have discovered novel plant extracts that activate IRS-2 signaling in 32DIRS-2 cells. HPRL has filed patents describing plant extracts with insulin-like, IRS-2 activating pharmacological properties. One of these plant extracts, now designated HP-211, activates the IRS-2 signal transduction cascade. HP-211 exhibits ?100% of the IRS-2 signaling activity as compared to Insulin in cell- based assays in vitro. Preliminary in vivo efficacy and safety data for this extract in mice demonstrate that HP-211 is at least as effective as metformin in a short term studies. SBIR funding is requested to enable the isolation and characterization one or more of the active natural product compounds from HP-211 that activate IRS-2 signaling. In Phase II, we intend to further investigate the safety and efficacy of the isolated natural product compounds with a goal of developing a therapeutic treatment for diabetes and related metabolic disorders. Compounds isolated from HP-211 will comprise a significant and innovative new area of therapeutic discovery with great potential to treat and possibly even prevent metabolic disorders such as diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43DK107190-01A1
Application #
9047104
Study Section
Special Emphasis Panel (ZRG1-IMST-L (11))
Program Officer
Arreaza-Rubin, Guillermo
Project Start
2015-09-24
Project End
2016-09-23
Budget Start
2015-09-24
Budget End
2016-09-23
Support Year
1
Fiscal Year
2015
Total Cost
$170,341
Indirect Cost
Name
Housey Pharmaceutical Research Lab
Department
Type
DUNS #
611659819
City
Southfield
State
MI
Country
United States
Zip Code
48076